IP03-22 efficacy of rezum therapy in acute urinary retention DUE to benign prostatic hyperplasia: analysis of clinical outcomes and factors associated with treatment failure
Abstract
INTRODUCTION AND OBJECTIVE: Acute urinary retention (AUR), often secondary to benign prostatic hyperplasia (BPH), signi fi - cantly impacts patients ’ quality of life and frequently requires surgical intervention such as transurethral resection of the prostate (TURP) or Holmium laser enucleation of the prostate (HoLEP). Since the COVID-19 pandemic, prolonged wait times for surgery have left many AUR patients reliant on catheters, potentially increasing complications, urological visits, and overall healthcare costs. The fi nancial burden of extended AUR management, particularly in systems with long surgical wait times, has not been thoroughly evaluated. Our study aims to assess the healthcare costs associated with AUR in patients awaiting HoLEP, using data from an academic health centre in Quebec. We hypothesized that longer wait times and resulting complications drive up resource utilization and costs. METHODS: In this retrospective study, we examined 91 patients with BPH-related AUR on the HoLEP waitlist at our institution from September 2021 to 2024. We recorded wait time, outpatient urological and ER visits, interventions, and associated costs obtained from our institution ’ s cost centre. Continuous variables were reported as means (standard deviation [SD]) or medians (interquartile range [IQR]) as appropriate. Data was analyzed using IBM SPSS. RESULTS: The mean age of patients was 71.0 years (SD 8.0), with a mean prostate size of 122.5 grams (SD 53.5). A total of 55 ER…
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.